Trastuzumab (Anti-HER2) is a recombinant humanized monoclonal antibody targeting HER2 antigen, which is overexpressed in invasive breast cancers. Trastuzumab has been used for the research of HER2 positive Metastatic Breast and Gastric Cancer.
Trastuzumab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to HER2 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Trastuzumab-SAP eliminates cells expressing human HER2. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
Special offer!
Fill out this form
to get your free Rippy’s Pad
mouse pad.
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: trastuzumab, HER2, breast cancer, metastatic, gastric, immunotoxin, streptavidin, saporin